Breyanzi (lisocabtagene maraleucel) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up log in
About MyLymphomaTeam
Powered By

Breyanzi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory large B-cell lymphoma who have been treated with at least two previous therapies. Breyanzi is also referred to by its drug name, lisocabtagene maraleucel.

Breyanzi is a new type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Breyanzi is made from a person’s own T cells that have been harvested and genetically engineered to target lymphoma cells. Breyanzi is believed to work by attacking and killing lymphoma cells.

How do I take it?
Since Breyanzi is manufactured from your own cells, the first step is having your T cells harvested at a clinic in a process similar to receiving a blood transfusion. Next, the cells are frozen and sent to the manufacturer’s laboratory, where they are genetically altered. The manufacturing process takes three to four weeks. Finally, Breyanzi is shipped to your health care provider.

Prescribing information states that Breyanzi is administered intravenously as a three day infusion after completing lymphodepleting chemotherapy.

Breyanzi comes in the form of an injectable suspension.

Side effects
The FDA-approved label for Breyanzi lists common side effects including fatigue, nausea, vomiting, diarrhea, constipation, abdominal pain, headache, dizziness, fast heartbeat, and swelling.

Cytokine release syndrome (CRS) is both common and potentially severe in people who take Breyanzi. CRS, which can be potentially fatal, can include fever, low blood pressure, rapid heart beat, and neurological side effects such as seizures, hallucinations, and tremors.

Rare but serious side effects listed for Breyanzi include hypersensitivities, serious infection, and neurologic toxicities.

For more details about this treatment, visit:

Breyanzi — Bristol Myers Squibb

Breyanzi — RxList

Continue with Facebook
Continue with Google
Your privacy is our priority. By continuing, you accept our Terms of Use and Privacy Policy.
Already a Member? Log in